Published in J Med Virol on May 01, 1991
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol (1992) 2.35
Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev (1999) 1.83
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol (2006) 1.73
Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 1.67
Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev (2004) 1.67
Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 1.55
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection. J Virol (2008) 1.07
Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol (2003) 1.00
Hyperresponsiveness to inhaled but not intravenous methacholine during acute respiratory syncytial virus infection in mice. Respir Res (2005) 0.94
Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine (2007) 0.92
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog (2015) 0.89
RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res (2009) 0.89
Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol J (2006) 0.88
T cell redistribution kinetics after secondary infection of BALB/c mice with respiratory syncytial virus. Clin Exp Immunol (1993) 0.86
Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol (2014) 0.84
Genomewide association analysis of respiratory syncytial virus infection in mice. J Virol (2009) 0.79
Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol (2005) 0.76
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med (2000) 8.46
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol (1969) 3.49
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis (1990) 2.18
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Comparison of competitive and indirect enzyme-linked immunosorbent assays for detection of bluetongue virus antibodies in serum and whole blood. J Clin Microbiol (1987) 2.07
Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol (1980) 1.97
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Temperature-sensitive mutants of respiratory syncytial virus. J Virol (1969) 1.94
Cytotoxic T-cell response to respiratory syncytial virus in mice. J Virol (1985) 1.92
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine. J Immunol (1969) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr (2000) 1.85
Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis (1994) 1.78
Adenovirus infections in young children. Pediatrics (1985) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis (1995) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Cytomegalovirus pneumonia in two infants recently adopted from China. Clin Infect Dis (1999) 1.65
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics (1997) 1.51
Temperature-sensitive mutants of respiratory syncytial virus: in-vivo studies in hamsters. J Infect Dis (1970) 1.51
Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis (1980) 1.47
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2). J Pediatr (1975) 1.45
Candidate AIDS vaccines. N Engl J Med (1995) 1.41
Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis (1983) 1.41
Vaccine-induced hypersensitivity: reactions to live measles and mumps vaccine in prior recipients of inactivated measles vaccine. J Pediatr (1969) 1.40
Diphtheria outbreaks in immunized populations. N Engl J Med (1988) 1.38
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine (1999) 1.37
Genetic studies of respiratory syncytial virus temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.36
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis (1995) 1.36
Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med (1977) 1.32
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr (1976) 1.31
Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol (1996) 1.29
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis (1977) 1.26
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus. Infect Immun (1980) 1.19
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 1.19
Electron microscopic studies of respiratory syncytial temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.16
Poliovirus antibody response in patients with acute leukemia. J Pediatr (1971) 1.16
Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis (1981) 1.15
Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun (1983) 1.14
Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr (1982) 1.14
Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) (2003) 1.13
The role of immunoglulins in the mechanism of mucosal immunity to virus infection. Pediatr Clin North Am (1970) 1.13
Role of respiratory tract proteases in infectivity of influenza A virus. J Infect Dis (1987) 1.13
Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis (1976) 1.12
Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis (1971) 1.12
A colorimetric microtiter plate PCR system detects respiratory syncytial virus in nasal aspirates and discriminates subtypes A and B. Diagn Microbiol Infect Dis (1999) 1.11
A comparison of five serological tests for bovine brucellosis. Can J Vet Res (1986) 1.10
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine (2000) 1.07
Terrapene heart (TH-1), a continuous cell line from the heart of the box turtle Terrapene carolina. Exp Cell Res (1967) 1.06
Isolation and characterization of viruses from the kidneys of Rana pipiens with renal adenocarcinoma before and after passage in the red eft (Triturus viridescens). J Virol (1968) 1.06
Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res (2011) 1.05
Growth curve studies of the suckling mouse cataract agent in individual compartments of the eye. Proc Soc Exp Biol Med (1969) 1.04
Lack of comparability between commonly used serological assays of immune response to Haemophilus influenzae vaccine. J Infect Dis (1987) 1.04
Application of a timing protocol to the reduction of inter-plate variability in the indirect enzyme immunoassay for detection of anti-Brucella antibody. J Immunoassay (1985) 1.04
Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine (1999) 1.04
Eustachian tube histopathology during experimental influenza A virus infection in the chinchilla. Ann Otol Rhinol Laryngol (1987) 1.03
An outbreak of airborne nosocomial varicella. Pediatrics (1982) 1.03
Ureaplasma urealyticum polyarthritis in agammaglobulinemia. Pediatr Infect Dis (1986) 1.02
Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res (1993) 1.02